Browse > Article
http://dx.doi.org/10.14579/MEMBRANE_JOURNAL.2020.30.6.373

Ultrafiltration and Diafiltration Processes for Concentration and Formulation of Antibody-based Therapeutics  

Lee, Jieun (Department of Biotechnology, Sungshin Women's University)
Lee, Jiyoon (Department of Biotechnology, Sungshin Women's University)
Baek, Youngbin (Department of Biotechnology, Sungshin Women's University)
Publication Information
Membrane Journal / v.30, no.6, 2020 , pp. 373-384 More about this Journal
Abstract
Antibody-based therapeutics have been receiving great attention as a representative biopharmaceutical, in which many researches are also carried out for its commercialization. The downstream process is considered an important part of the manufacturing processes of antibody-based therapeutics since it directly affects the performance and stability of products. Ultrafiltration/diafiltration (UF/DF), mostly performed in final step during downstream process, are used for the final concentration and formulation of antibody-based therapeutics. This paper reviewed the major products of the UF membrane, process characteristics, and recent research trends in UF/DF.
Keywords
ultrafiltration; diafiltration; concentration; formulation; antibody-based therapeutics;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 A. U. Borwankar, A. K. Dinin, J. R. Laber, A. Twu, B. K. Wilson, J. A. Maynard, T. M. Truskett, and K. P. Johnston, "Tunable equilibrium nanocluster dispersions at high protein concentrations", Soft Matter, 9, 1766 (2013).   DOI
2 N. Inoue, E. Takai, T. Arakawa, and K. Shiraki, "Specific decrease in solution viscosity of antibodies by arginine for therapeutic formulations", Mol. Pharm., 11, 1889 (2014).   DOI
3 Z. Guo, A. Chen, R. A. Nassar, B. Helk, C. Mueller, Y. Tang, K. Gupta, and A. M. Klibanov, "Structure-activity relationship for hydrophobic salts as viscosity-lowering excipients for concentrated solutions of monoclonal antibodies", Pharm. Res., 29, 3102 (2012).   DOI
4 A. U. Borwankar, B. J. Dear, A. Twu, J. J. Hung, A. K. Dinin, B. K. Wilson, J. Yue, J. A. Maynard, T. M. Truskett, and K. P. Johnston, "Viscosity reduction of a concentrated monoclonal antibody with arginine.HCl and arginine.glutamate", Ind. Eng. Chem. Res., 55, 11225 (2016).   DOI
5 https://www.repligen.com/technologies/tangenx-tff/sius-single-use, September 21 (2020).
6 Y. Baek, N. Singh, A. Arunkumar, M. Borys, Z. J. Li, and A. L. Zydney, "Ultrafiltration behavior of monoclonal antibodies and Fc-fusion proteins: Effects of physical properties", Biotechnol. Bioeng., 114, 2057 (2017).   DOI
7 M. R. Stoner, N. Fischer, L. Nixon, S. Buckel, M. Benke, F. Austin, T. W. Randolph, and B. S. Kendrick, "Protein-solute interactions affect the outcome of ultrafiltration/diafiltration operations", J. Pharm. Sci., 93, 2332 (2004).   DOI
8 G. R. Bolton, A. W. Boesch, J. Basha, D. P. LaCasse, B. D. Kelley, and H. Acharya, "Effect of protein and solution properties on the donnan effect during the ultrafiltration of proteins", Biotechnol. Prog., 27, 140 (2011).   DOI
9 F. Miao, A. Velayudhan, E. DiBella, J. Shervin, M. Felo, M. Teeters, and P. Alred, "Theoretical analysis of excipient concentrations during the final ultrafiltration/diafiltration step of therapeutic antibody", Biotechnol. Prog., 25, 964 (2009).   DOI
10 M. Teeters, D. Bezila, T. Benner, P. Alfonso, and P. Alred, "Predicting diafiltration solution compositions for final ultrafiltration/diafiltration steps of monoclonal antibodies", Biotechnol. Bioeng., 108, 1338 (2011).   DOI
11 Y. Baek, N. Singh, A. Arunkumar, A. Borwankar, and A. L. Zydney, "Mass balance model with donnan equilibrium accurately describes unusual pH and excipient profiles during diafiltration of monoclonal antibodies", Biotechnol. J., 14, 1800517 (2019).   DOI
12 C. Casey, T. Gallos, Y. Alekseev, E. Ayturk, and S. Pearl, "Protein concentration with single-pass tangential flow filtration (SPTFF)", J. Memb. Sci., 384, 82 (2011).   DOI
13 J. Dizon-Maspat, J. Bourret, A. D'Agostini, and F. Li, "Single pass tangential flow filtration to debottleneck downstream processing for therapeutic antibody production", Biotechnol. Bioeng., 109, 962 (2012).   DOI
14 Lg경제연구원, "차세대 바이오 의약품, 세포치료제 시장 현황과 전망" (2017).
15 L. Fernandez-Cerezo, A. C. M. E. Rayat, A. Chatel, J. M. Pollard, G. J. Lye, and M. Hoare, "The prediction of the operating conditions on the permeate flux and on protein aggregation during membrane processing of monoclonal antibodies", J. Memb. Sci., 596, 117606 (2020).   DOI
16 L. M. Weiner, R. Surana, and S. Wang, "Monoclonal antibodies: Versatile platforms for cancer immunotherapy", Nat. Rev. Immunol., 10, 317 (2010).   DOI
17 W. Wang, S. Singh, D. L. Zeng, K. King, and S. Nema, "Antibody structure, instability, and formulation", J. Pharm. Sci., 96, 1 (2007).   DOI
18 www.evaluate.com/PharmaWorldPreview2019, September 11 (2020).
19 한국수출입은행 해외경제연구소, "세계 바이오의약품산업 동향 및 전망" (2019).
20 A. Mehta, "Downstream Processing for Biopharmaceuticals Recovery", pp. 163-190, Springer, Berlin (2019).
21 R. van Reis and A. Zydney, "Bioprocess membrane technology", J. Memb. Sci., 297, 16 (2007).   DOI
22 T. H. Choi and H. B. Park, "Membrane and virus filter trends in the processes of biopharmaceutical production", Membr. J., 30, 9 (2020).   DOI
23 https://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma-Aldrich/General_Information/2/pellicon3_30kd_cleanability_techbrief-tb1241en-mk.pdf (2017).
24 https://www.pall.com/content/dam/pall/biopharm/lit-library/non-gated/procedures/09.3090_USTR2433b_T_Series_Cassettes_Omega_IFU_EN.pdf, December 9 (2009).
25 https://www.emdmillipore.com/Web-CA-Site/en_CA/-/CAD/ShowDocument-Pronet?id=201501.131, March (2018).
26 http://tangenx.com/wp-content/uploads/2015/01/TX-ProStream-HD.pdf, January (2015).
27 https://www.zind-vt.com/pdfs/HyStream.pdf, January (2015).
28 https://shop.pall.com/us/en/biotech/tangential-flowfiltration/cassettes/zidgri78m0j, September 11 (2020).
29 https://www.sartorius.com/shop/medias/-datasheet-enData-Hydrosart-Ultraf-White-Silicone-SPC2063-e.pdf (2019).
30 www.sartorius-stedim.com, September 11 (2020).
31 https://shop.pall.com/us/en/biotech/tangential-flowfiltration/cassettes/zidgri78lp2, September 11 (2020).
32 https://shop.pall.com/us/en/biotech/tangential-flowfiltration/cassettes/zidgri78m0j, September 11 (2020).
33 https://www.repligen.com/technologies/tangenx-tff/pro-reusable, September 11 (2020).
34 A. Arunkumar, N. Singh, E. G. Schutsky, M. Peck, R. K. Swanson, M. C. Borys, and Z. J. Li, "Effect of channel-induced shear on biologics during ultrafiltration/diafiltration (UF/DF)", J. Memb. Sci., 514, 671 (2016).   DOI
35 https://www.emdmillipore.com/Web-CA-Site/en_CA/-/CAD/ShowDocument-Pronet?id=201306.4194, December (2018).
36 https://bioprocessintl.com/downstream-processing/filtration/integrity-testing-of-ultrafiltration-systemsfor-biopharmaceutical-applications-335646/, August 31 (2020).
37 https://www.emdmillipore.com/Web-US-Site/en_CA/-/USD/ShowDocument-Pronet?id=201306.11634, May (2017).
38 A. M. Scott, J. D. Wolchok, and L. J. Old, "Antibody therapy of cancer", Nat. Rev. Cancer, 12, 278 (2012).   DOI
39 A. L. Nelson, E. Dhimolea, and J. M. Reichert, "Development trends for human monoclonal antibody therapeutics", Nat. Rev. Drug Discov., 9, 767 (2010).   DOI
40 Y. Baek, D. Yang, and A. L. Zydney, "Development of a hydrodynamic cleaning cycle for ultrafiltration/diafiltration processes used for monoclonal antibody formulation", Ind. Eng. Chem. Res., 57, 16110 (2018).   DOI
41 Y. Baek and A. L. Zydney, "Intermolecular interactions in highly concentrated formulations of recombinant therapeutic proteins", Current Opinion in Biotechnology, 53, 59 (2018).   DOI
42 https://www.emdmillipore.com/Web-PR-Site/en_CA/-/USD/ShowDocument-File?ProductSKU=MM_NFC9947&DocumentId=201306.4192.ProNet&DocumentType=UG&Language=EN&Country=NF&Origin=PDP, February (2019).
43 https://www.pall.com/content/dam/pall/biopharm/lit-library/non-gated/procedures/09.3100_USTR2453b_T_Series_Cassettes_Omega_Delta_IFU_EN.pdf, December 9 (2009).
44 https://www.pall.com/content/dam/pall/biopharm/lit-library/non-gated/procedures/11.7322_USTR2662(3)_T_Series_Cassettes_Delta_IFU_EN.pdf, August 11 (2011).
45 P. Ng, J. Lundblad, and G. Mitra, "Note: optimization of solute separation by diafiltration", Separation Science, 11, 499 (1976).   DOI
46 K. McKeage, "A review of CT-P13: An infliximab biosimilar", BioDrugs, 28, 313 (2014).   DOI
47 W. Du and A. M. Klibanov, "Hydrophobic salts markedly diminish viscosity of concentrated protein solutions", Biotechnol. Bioeng., 108, 632 (2011).   DOI
48 T. M. Scherer, "Cosolute effects on the chemical potential and interactions of an IgG1 monoclonal antibody at high concentrations", J. Phys. Chem. B, 117, 2254 (2013).   DOI
49 K. P. Johnston, J. A. Maynard, T. M. Truskett, A. U. Borwankar, M. A. Miller, B. K. Wilson, A. K. Dinin, T. A. Khan, and K. J. Kaczorowski, "Concentrated dispersions of equilibrium protein nanoclusters that reversibly dissociate into active monomers", ACS Nano, 6, 1357 (2012).   DOI